MX2009003256A - Inhibidor de la activacion de stat3/5. - Google Patents

Inhibidor de la activacion de stat3/5.

Info

Publication number
MX2009003256A
MX2009003256A MX2009003256A MX2009003256A MX2009003256A MX 2009003256 A MX2009003256 A MX 2009003256A MX 2009003256 A MX2009003256 A MX 2009003256A MX 2009003256 A MX2009003256 A MX 2009003256A MX 2009003256 A MX2009003256 A MX 2009003256A
Authority
MX
Mexico
Prior art keywords
group
stat3
activation inhibitor
hydrogen atom
present
Prior art date
Application number
MX2009003256A
Other languages
English (en)
Inventor
Takashi Suzuki
Kazuhisa Sugiyama
Kazuo Sekiguchi
Kenji Yoshida
Takumi Sumida
Naoto Ohi
Mitsuhiro Okuno
Kunihiko Kiyono
Seiji Akamatsu
Takeshi Kodama
Yasuo Yanagihara
Kenji Ohnishi
Masaaki Motoyama
Yutaka Ohbuchi
Takashi Watanabe
Kazuhiko Hayashi
Hideo Tanaka
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2009003256A publication Critical patent/MX2009003256A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un objetivo de la presente invención es proporcionar un inhibidor de la activación de STAT3/5. La presente invención proporciona un inhibidor de la activación de STAT3/5 que contiene un compuesto aromático representado por la fórmula general o una sal del mismo como un ingrediente activo: (ver fórmula (1)) en donde X1. representa un átomo de nitrógeno o un grupo -CH=, R1 representa un grupo -Z-R6, en la cual Z representa un grupo -CO-, un grupo -CH(OH)- o similares, R6 representa un grupo heterocíclico, saturado o insaturado, monocíclico, dicíclico o tricíclico de 5 a 15 miembros que tiene de 1 a 4 átomos de nitrógeno, átomos de oxígeno o átomos de azufre, R2 representa un átomo de hidrógeno o un átomo de halógeno, Y representa un grupo -O-, un grupo -CO-, un grupo -CH(OH)- o un grupo alquileno inferior y A representa un grupo (ver formula) en donde R3 representa un átomo de hidrógeno, un grupo alcoxi inferior o similares, p representa 1 o 2, R4 representa un grupo imidazolil-alquilo inferior o similares.
MX2009003256A 2006-10-02 2007-10-02 Inhibidor de la activacion de stat3/5. MX2009003256A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006271172 2006-10-02
PCT/JP2007/069645 WO2008044667A1 (en) 2006-10-02 2007-10-02 Stat3/5 activation inhibitor

Publications (1)

Publication Number Publication Date
MX2009003256A true MX2009003256A (es) 2009-04-08

Family

ID=38896700

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003256A MX2009003256A (es) 2006-10-02 2007-10-02 Inhibidor de la activacion de stat3/5.

Country Status (20)

Country Link
US (2) US8263599B2 (es)
EP (2) EP2089373A1 (es)
JP (1) JP5068821B2 (es)
KR (1) KR101148805B1 (es)
CN (1) CN101522657B (es)
AR (1) AR063073A1 (es)
AU (1) AU2007305511A1 (es)
BR (1) BRPI0717218A2 (es)
CA (1) CA2665000C (es)
HK (1) HK1131619A1 (es)
IL (1) IL197723A (es)
MX (1) MX2009003256A (es)
MY (1) MY150229A (es)
NO (1) NO20090856L (es)
NZ (1) NZ598061A (es)
RU (1) RU2489148C2 (es)
TW (1) TWI336699B (es)
UA (1) UA95978C2 (es)
WO (1) WO2008044667A1 (es)
ZA (1) ZA200901874B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100927563B1 (ko) 2004-08-06 2009-11-23 오쓰까 세이야꾸 가부시키가이샤 방향족 화합물
AU2006290442B2 (en) 2005-09-16 2010-07-29 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis C
ZA200804445B (en) * 2005-12-05 2009-11-25 Otsuka Pharma Co Ltd Diarylether derivatives as antitumor agents
NZ602099A (en) 2008-07-10 2014-06-27 Pharma Ip General Inc Ass Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
JP5688918B2 (ja) * 2009-04-28 2015-03-25 大塚製薬株式会社 医薬組成物
EP2520575B1 (en) 2009-12-28 2016-11-30 General Incorporated Association Pharma Valley Project Supporting Organisation 1,3,4-oxadiazole-2-carboxamide compound
AR080057A1 (es) 2010-01-29 2012-03-07 Otsuka Pharma Co Ltd Piridinas disustituidas como anticancerigenos
TWI526431B (zh) * 2010-10-04 2016-03-21 大塚製藥股份有限公司 雜環化合物
WO2013020372A1 (zh) * 2011-08-09 2013-02-14 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
TW201329025A (zh) 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
JP6066806B2 (ja) * 2012-04-03 2017-01-25 大塚製薬株式会社 医薬
BR112014029439A2 (pt) * 2012-05-25 2017-06-27 Governing Council Univ Toronto derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos
CN103880707B (zh) * 2012-12-19 2016-04-13 上海交通大学医学院 Stat3小分子抑制剂及其应用
EP3019475A1 (en) * 2013-07-08 2016-05-18 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
NZ726874A (en) * 2014-05-19 2018-03-23 Merial Inc Anthelmintic compounds
US10519107B2 (en) 2014-05-30 2019-12-31 The Governing Council Of The University Of Toronto Sulfonamide compounds and their use as STAT5 inhibitors
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
CN110573151A (zh) 2017-04-26 2019-12-13 辛辛那提大学 用于治疗急性髓性白血病的方法、试剂和组合物
TWI650120B (zh) * 2017-07-21 2019-02-11 寶騰生醫股份有限公司 一種醫藥組成物用於製備治療或預防個體感染病毒之藥物的用途
US10882821B1 (en) 2017-09-26 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
JP7455741B2 (ja) 2018-06-01 2024-03-26 正憲 原 植物の栽培方法及び植物の栽培装置
WO2020200154A1 (zh) * 2019-03-30 2020-10-08 上海凌达生物医药有限公司 一类噻吩并氮杂环类化合物、制备方法和用途
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
WO2021024375A1 (ja) 2019-08-06 2021-02-11 正月 白川 植物の栽培方法及び植物の栽培装置
RU2742188C1 (ru) * 2020-07-22 2021-02-03 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. Способ лечения оптической нейропатии у больных с отечным экзофтальмом
CN117362206B (zh) * 2023-12-08 2024-02-20 四川大学华西第二医院 一类芳基磺酰胺类化合物、合成方法及用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE629102A (es) 1961-03-29
US3715375A (en) 1970-09-17 1973-02-06 Merck & Co Inc New diphenyl sulfones
NL7111711A (es) 1970-09-17 1972-03-21
GB1494117A (en) 1974-11-02 1977-12-07 Bayer Ag Process for the preparation of acid amides
DE2707659A1 (de) 1977-02-23 1978-08-24 Bayer Ag Selbstvernetzbare polyurethane
DE2707660C2 (de) 1977-02-23 1985-12-19 Bayer Ag, 5090 Leverkusen Abspalter- und Diolrest enthaltende Diisocyanat-Addukte, ihre Herstellung und Verwendung
DE2812252A1 (de) 1978-03-21 1979-10-04 Bayer Ag 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
EP0500495A3 (en) 1991-02-21 1993-04-07 Ciba-Geigy Ag Thermosetting composition
DE69314718T2 (de) 1992-07-21 1998-02-26 Ciba Geigy Ag Oxamidsäure-Derivate als hypocholesterämische Mittel
AU7006094A (en) 1993-06-30 1995-01-24 Wellcome Foundation Limited, The Anti-atherosclerotic diaryl compounds
IL122341A0 (en) 1995-06-07 1998-04-05 Inst Materia Medica Retinoid derivatives and their use
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
JP2002502845A (ja) 1998-02-06 2002-01-29 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ トリプターゼ阻害物質
ES2233025T3 (es) 1998-02-06 2005-06-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Agente inhibidores de la triptasa.
AR015733A1 (es) 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
TWI245035B (en) 1998-06-26 2005-12-11 Ono Pharmaceutical Co Amino acid derivatives and a pharmaceutical composition comprising the derivatives
AU750670B2 (en) 1998-07-24 2002-07-25 Teijin Limited Anthranilic acid derivatives
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
CA2362401A1 (en) 1999-02-04 2000-08-10 Paul Fleming G-protein coupled heptahelical receptor binding compounds and methods of use thereof
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
US6159694A (en) 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
CA2377771A1 (en) 1999-07-01 2001-01-11 Ajinomoto Co., Inc. Heterocyclic compounds and medical use thereof
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
JP2001089450A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ピリジン誘導体含有医薬製剤
EP1256341A4 (en) 2000-02-15 2004-12-08 Teijin Ltd ANTI-CANCER MEDICINAL PRODUCT COMPRISING AN ANTHRANILIC ACID DERIVATIVE AS AN ACTIVE INGREDIENT
BR0111206A (pt) 2000-05-22 2003-04-15 Aventis Pharma Inc Derivados de arilmetilamina para uso como inibidores de triptase
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
JP2004506735A (ja) 2000-08-18 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用キヌクリジン置換アリール化合物
IL155097A0 (en) 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
AU2002223626A1 (en) 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
EP1211235A3 (en) 2000-11-30 2004-01-02 JFE Chemical Corporation Preparation process of 4,4'-Dicarboxydiphenyl ethers or derivatives thereof
JP2004269356A (ja) 2000-12-27 2004-09-30 Ajinomoto Co Inc 創傷部癒着防止剤
GB2374009A (en) 2001-02-12 2002-10-09 Novartis Ag Method of treating hair loss
KR20040012956A (ko) 2001-06-20 2004-02-11 화이자 프로덕츠 인코포레이티드 설폰산 유도체
CA2455773A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-aryl 7-aza¬2.2.1|bicycloheptanes for the treatment of disease
ATE456559T1 (de) 2001-10-22 2010-02-15 Pfizer Prod Inc Piperazinderivate mit ccr1-rezeptor- antagonistischer wirkung
WO2003035602A1 (fr) 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
MXPA04007936A (es) 2002-02-15 2004-11-26 Upjohn Co Compuestos de aril-sustituidos para el tratamiento de enfermedades.
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
JP2004035475A (ja) 2002-07-03 2004-02-05 Ajinomoto Co Inc ＴＧＦβ作用抑制剤
TW201018661A (en) 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7977387B2 (en) 2003-07-24 2011-07-12 Leo Pharma A/S Aminobenzophenone compounds
KR100927563B1 (ko) 2004-08-06 2009-11-23 오쓰까 세이야꾸 가부시키가이샤 방향족 화합물
ZA200804445B (en) 2005-12-05 2009-11-25 Otsuka Pharma Co Ltd Diarylether derivatives as antitumor agents
TWI440638B (zh) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物

Also Published As

Publication number Publication date
MY150229A (en) 2013-12-31
IL197723A (en) 2015-02-26
AR063073A1 (es) 2008-12-23
AU2007305511A1 (en) 2008-04-17
KR20090043008A (ko) 2009-05-04
TW200823189A (en) 2008-06-01
UA95978C2 (ru) 2011-09-26
HK1131619A1 (en) 2010-01-29
CN101522657B (zh) 2014-10-15
TWI336699B (en) 2011-02-01
US8263599B2 (en) 2012-09-11
ZA200901874B (en) 2010-07-28
IL197723A0 (en) 2009-12-24
EP2612858A1 (en) 2013-07-10
JP5068821B2 (ja) 2012-11-07
RU2009116653A (ru) 2010-11-10
CA2665000A1 (en) 2008-04-17
NZ598061A (en) 2013-05-31
KR101148805B1 (ko) 2012-07-10
RU2489148C2 (ru) 2013-08-10
JP2010505762A (ja) 2010-02-25
BRPI0717218A2 (pt) 2013-09-24
NO20090856L (no) 2009-03-27
US20120322807A1 (en) 2012-12-20
WO2008044667A1 (en) 2008-04-17
EP2089373A1 (en) 2009-08-19
CA2665000C (en) 2015-03-24
US20100210661A1 (en) 2010-08-19
CN101522657A (zh) 2009-09-02

Similar Documents

Publication Publication Date Title
MX2009003256A (es) Inhibidor de la activacion de stat3/5.
TW200619214A (en) Aromatic compound
MY146514A (en) Diarylether derivatives as antitumor agents
TW200731013A (en) Salt suitable for an acid generator and a chemically amplified resist composition containing the same
MX2009009540A (es) Inhibidores de metaloproteasa que contienen una porcion heterociclica.
UA88329C2 (en) Dna-pk inhibitors
MY152972A (en) Azabicyclo compound and salt thereof
TW200728914A (en) A salt suitable for an acid generator and a chemically amplified resist composition containing the same
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
TW200621786A (en) Condensed pyrazole derivatives, their preparation and application in therapeutics
DE602006007012D1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
SG140618A1 (en) Amide compound
MY179032A (en) Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
IN2012DN01325A (es)
MD20110063A2 (en) Herbicidal compositions containing benzoylpyrazole compounds
TW200719089A (en) A salt suitable for an acid generator and a chemically amplified resist composition containing the same
MY147780A (en) Carboxamide compounds and their use as calpain inhibitors
MX2009003073A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk.
TW200732284A (en) Amine compound and pharmaceutical use thereof
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
EP1741714A4 (en) HETEROCYLIC COMPOUND AND ANTI-MALIGNANT TUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT
UA102310C2 (ru) Гетероциклические сульфонамиды, их применение и фармацевтические композиции

Legal Events

Date Code Title Description
FG Grant or registration